Photo by Cheryl Gerber via Abaca/Sipa USA
EMA Expected To Approve Janssen Vaccine By March
WASHINGTON (AP) – An analysis by U.S. regulators say Johnson & Johnson’s single-dose vaccine protects against COVID-19.
The report Wednesday confirmed the vaccine is about 66% effective overall at preventing moderate to severe COVID-19.
On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the vaccine. The FDA is expected to make a final decision within days.
If the FDA clears the J&J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.
J&J tested its single-dose option in 44,000 people in the U.S., Latin America and South Africa. J&J previously announced the vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19, compared with 66% in Latin America and 57% in South Africa.
Still, in every country it was highly effective against the most serious symptoms, and early study results showed no hospitalizations or deaths starting 28 days after vaccination.
